Alveolar rhabdomyosarcoma originating from the uterine cervix

Cervical alveolar rhabdomyosarcoma is a rare condition associated with poor prognosis. An 18-year-old patient presented with vaginal bleeding and a protruding mass from the vagina. Biopsy of the mass revealed alveoler rhabdomyosarcoma (ARMS), and radiological evaluation demonstrated that it originated from the uterine cervix. First, Wertheim's operation was carried out followed by four cycles of vincristine, actinomycine-D, ifosfamide (VAI) chemotherapy. However, the disease relapsed within three months, and the patient died of disease progression. Despite combination treatment, we could not achieve a desirable survival advantage in ARMS. Future studies may unveil the genomic profile of this rare condition, leading to invention of targeted therapies, which is the emerging trend in the treatment of sarcomas.

Alveolar rhabdomyosarcoma; Cervix; Treatment

[1] Emerich J.,Senkus E., Konefka T.: “Alveolar rhabdomyosarcoma of the uterine cervix”. Gynecol. Oncol., 1996, 3, 398.

[2] Ng T.Y., Loo K.T., Leung T.W., Lo S.H., Yuen K.K.: “Alveolar rhab-domyosarcoma of the cervix”. Gynecol. Oncol., 2003, 91, 623.

[3] Case A.S., Kirby T.O., Conner M.G., Huh W.K.: “A case report of rhabdomyosarcoma of the uterus with uterin inversion”. Gynecol. Oncol., 2005, 96, 850.

[4] Pappo A.S., Lyden E., Breneman J., Wiener E., Teot E., Meza J. et al.: “Up front window trial of Topotecan in previously untreated chidren and adolescents with metastatic rhabdomyosarcoma: An Intergroup Rhabdomyosarcoma Study”. J. Clin. Oncol., 2001, 19, 213.

[5] Baker K.S., Anderson J.R., Link M.P., Grier H.E., Qualman S.J., Maurer H.M. et al.: “Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: Results from the Intergroup Rhabdomyosarcoma Study IV”. J. Clin. Oncol., 2000, 18, 2427.

[6] Parham D., Ellison D.: “Rhabdomyosarcomas in adults and children: an update”. Arch. Pathol. Lab. Med., 2006, 130, 1454.

[7] Crist W.M., Anderson J.R., Meza J.L., Fryer C., Raney R.B., Ruymann F.B. et al.: “Intergroup rhabdomyosarcoma study IV: results for patients with nonmetastatic disease”. J. Clin. Oncol., 2001, 19, 3091.

[8] Raney R.B., Maurer H.M., Anderson J.R., Andrassy J.R., Donaldson S.S., Qualman S.J. et al.: “The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocol”. Sarcoma, 2001, 5, 9.